The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Imdyllytra (tarlatamab) for the ...

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

CARsgen Therapeutics reports positive Phase II data for satri-cel in advanced gastric and GEJ cancers, meeting the primary ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...

China-based biotech Duality Biologics (DualityBio) yesterday revealed that Sino-American BeiGene has exercised its exclusive ...

TJ Bio has reportedly submitted a biologics license application (BLA) to China’s Center for Drug Evaluation for GX-H9 ...

China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal ...

The life sciences industry experienced volatility in 2024, marked by pipeline growth, biologics breakthroughs, and evolving ...

India's Parliamentary panel has come down heavily on the National Pharmaceutical Pricing Authority (NPPA) and directed it to ...

Novartis reports positive Phase III trial results for its gene therapy in spinal muscular atrophy Type 2, plans regulatory ...